High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.

Ständer, S; Bhatia, N; Gooderham, M J; Silverberg, J I; Thyssen, J P; Biswas, P; DiBonaventura, M; Romero, W; Farooqui, S A

Ständer, S; Bhatia, N; Gooderham, M J; Silverberg, J I; Thyssen, J P; Biswas, P; DiBonaventura, M; Romero, W; Farooqui, S A.

Afiliação

Ständer S; Department of Dermatology, Center for Chronic Pruritus, University Hospital, Münster, Germany.
Bhatia N; Therapeutics Clinical Research, San Diego, California, USA.
Gooderham MJ; SKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, Ontario, Canada.
Silverberg JI; The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Thyssen JP; Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Biswas P; Pfizer Inc., New York, New York, USA.
DiBonaventura M; Pfizer Inc., New York, New York, USA.
Romero W; Pfizer R & D UK Ltd., Kent, UK.
Farooqui SA; Global Product Development, Pfizer R & D UK Ltd., Sandwich, UK.

J Eur Acad Dermatol Venereol ; 36(8): 1308-1317, 2022 Aug.

Article em En | MEDLINE | ID: mdl-35462428

Assuntos

Dermatite Atópica; Adolescente; Adulto; Criança; Dermatite Atópica/diagnóstico; Dermatite Atópica/tratamento farmacológico; Método Duplo-Cego; Humanos; Pirimidinas; Qualidade de Vida; Índice de Gravidade de Doença; Sulfonamidas; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Tipo de estudo: Clinical_trials / Diagnostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google